tradingkey.logo

Sight Sciences Inc

SGHT
查看詳細走勢圖
8.440USD
0.000
收盤 12/23, 16:00美東報價延遲15分鐘
442.88M總市值
虧損本益比TTM

Sight Sciences Inc

8.440
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

+1.56%

1月

+16.25%

6月

+107.88%

今年開始到現在

+131.87%

1年

+136.41%

查看詳細走勢圖

TradingKey Sight Sciences Inc股票評分

單位: USD 更新時間: 2025-12-22

操作建議

Sight Sciences Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名91/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價6.42。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Sight Sciences Inc評分

相關信息

行業排名
91 / 208
全市場排名
216 / 4578
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 7 分析師
買入
評級
6.417
目標均價
-24.78%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Sight Sciences Inc亮點

亮點風險
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
業績增長期
公司處於發展階段,最新年度總收入79.87M美元
估值低估
公司最新PE估值-9.44,處於3年歷史低位
機構減倉
最新機構持股26.78M股,環比減少27.62%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉3.89K股

Sight Sciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Sight Sciences Inc簡介

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
公司代碼SGHT
公司Sight Sciences Inc
CEOBadawi (Paul)
網址https://www.sightsciences.com/

常見問題

Sight Sciences Inc(SGHT)的當前股價是多少?

Sight Sciences Inc(SGHT)的當前股價是 8.440。

Sight Sciences Inc 的股票代碼是什麼?

Sight Sciences Inc的股票代碼是SGHT。

Sight Sciences Inc股票的52週最高點是多少?

Sight Sciences Inc股票的52週最高點是8.800。

Sight Sciences Inc股票的52週最低點是多少?

Sight Sciences Inc股票的52週最低點是2.030。

Sight Sciences Inc的市值是多少?

Sight Sciences Inc的市值是442.88M。

Sight Sciences Inc的淨利潤是多少?

Sight Sciences Inc的淨利潤為-51.51M。

現在Sight Sciences Inc(SGHT)的股票是買入、持有還是賣出?

根據分析師評級,Sight Sciences Inc(SGHT)的總體評級為買入,目標價格為6.417。

Sight Sciences Inc(SGHT)股票的每股收益(EPS TTM)是多少

Sight Sciences Inc(SGHT)股票的每股收益(EPS TTM)是-0.894。
KeyAI